← Leaderboards
Zachary Scott Wallace
Massachusetts General Hospital
$1,528,318
Attributed
$1,919,573
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $782.5K · FY2018–23$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,919,573 · 3
By mechanism
K23$948,060 · 1
R01$782,510 · 1
R03$189,003 · 1
Top collaborators
- Jeffrey Andrew Sparks1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Mary B Rice$4,848,700
- Angela Bair Schmider$1,416,603
- M. Amin Arnaout$31,171,564
- Mark J Siedner$14,937,325
- Amy K Barczak$6,060,280
Others in their field
Other Emerging Leaders on “Cohort”
- Leonard Freedman · Leidos Biomedical Research, Inc.$70,225,348
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
- Julie Ake · National Institute Of Allergy And Infectious Diseases$52,642,120
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Scott Hensley · University Of Pennsylvania$47,346,110
- Susan M Landau · University Of California Berkeley$47,252,026
Research focus
CohortGeneral PopulationSamplingHigh RiskCardiovascular DiseasesMortalityEpidemiologyCaringInfectionCessation Of LifeVasculitisMortality RiskQuality Of LifeModels And SimulationAlgorithmsPatient OrientedAntineutrophil Cytoplasmic AntibodiesPositioning AttributeTreatment StrategyMethodologyMedical SchoolsKidney DiseasesMassachusettsMedicine
Grant awards (9)
Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases$782,510
R01 · FY2023 · AR
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis$179,280
K23 · FY2022 · AR · contact PI
Personalizing AAV Management by Leveraging Big Data: Targeting Complication Clusters$83,160
R03 · FY2022 · AR · contact PI
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years in ANCA-Associated Vasculitis$179,280
K23 · FY2021 · AR · contact PI
Personalizing AAV Management by Leveraging Big Data: Targeting Complication Clusters$105,843
R03 · FY2021 · AR · contact PI
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis$54,000
K23 · FY2021 · AR · contact PI
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis$178,380
K23 · FY2020 · AR · contact PI
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis$178,420
K23 · FY2019 · AR · contact PI
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated Vasculitis$178,700
K23 · FY2018 · AR · contact PI